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Cost-effectiveness analysis of
applying the Cholesterol and
Recurrent Events (CARE) study
protocol in Hong Kong
Objective. To determine the cost-effectiveness of secondary prevention
with pravastatin in Hong Kong patients with coronary heart disease and
average cholesterol levels.
Design. Cost-effectiveness analysis based on published results of the
CARE study.
Patients. Men and women post–myocardial infarction with average
cholesterol levels.
Main outcome measures. Cost-effectiveness analysis: cost per life saved,
cost per fatal or non-fatal coronary event prevented, cost per procedure
prevented, and cost per fatal or non-fatal stroke prevented. Cost-utility
analysis: gross cost and net cost per quality-adjusted life year gained
calculated using two alternative models.
Results. Cost per life saved or death prevented was HK$4 442 350 (non-
discounted); cost per fatal or non-fatal cardiac event prevented HK$1 146 413;
cost per procedure prevented HK$732 759; and cost per fatal or non-fatal
stroke prevented HK$2 961 566. Net cost per quality-adjusted life year
gained was HK$73 218 and HK$65 280 non-discounted, respectively
using the two alternative models.
Conclusions. The results of this study can assist in prioritising the use
of health care resources in Hong Kong but should be considered along-
side the benefits and costs of alternative interventions for coronary heart
disease.
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Introduction
From the economist’s point of view, resources in a
society are finite and limited. Every time resources are
deployed, the possibility of expending them for
alternative purposes (opportunity cost) is foregone. In
applying this concept to the health care system, priority
must be given to providing maximum benefit from the
available resources.1 However, should more weight be
given to maximising possible benefits for a selected
set of individuals, or to spreading benefit among a
maximum number of suitable persons (societal
perspective)? With respect to secondary prevention of
coronary disease events, the Scandinavian Simvastatin
Survival Study (4S) clearly demonstrated the benefits
of lipid-lowering therapy in a group of patients who
had high cholesterol levels.2 Further, the Cholesterol
and Recurrent Events (CARE) study raised the
possibility that benefits also extend to more typical at-
risk patients with average cholesterol levels.3 The
CARE study demonstrated that patients with a history
of myocardial infarction (MI) treated with pravastatin
experienced a significant reduction in the incidence of
coronary events, despite most patients having average
cholesterol levels.
The 4S showed the beneficial effect on mortality
and morbidity of lowering excessive cholesterol levels
with simvastatin in patients with coronary heart disease
(CHD). Its cost-effectiveness and favourable pharmaco-
economic implications have also been shown.4,5 Cost-
effectiveness of expensive drug treatments such as the
statins, however, depends on the risk of CHD.6 The
cholesterol level of the patient is one determinant of
this risk. It has yet to be shown whether treating patients
who have normal cholesterol levels with statins is a
relatively cost-effective option.
The concern of this study was to evaluate the CARE
approach from a Hong Kong perspective, with respect to
cost-effectiveness and cost-utility analyses. The major
endpoint in the cost-utility analysis was net cost per
quality-adjusted life year (QALY) gained, adjusting for
other less tangible monetary savings and benefits relevant
to the calculations of net costs.
Methods
Patients
In this analysis, the costs and benefits of using CARE
criteria and pravastatin 40 mg daily to treat a hypo-
thetical cohort of Hong Kong patients with the same
demographics and prognosis as those enrolled in the
CARE study were evaluated.
The CARE study recruited patients from 13
centres in Canada and 67 centres in the United States.3
Patients included men and postmenopausal women,
aged between 21 and 75 years, who had an acute MI
between 3 and 20 months before recruitment. Entry
criteria included plasma total cholesterol levels of
less than 240 mg/dL (<6.2 mmol/L), low-density
lipoprotein cholesterol levels of 115 to 174 mg/dL
(3.0 to 4.5 mmol/L), fasting triglyceride levels of less
than 350 mg/dL (<4.0 mmol/L), fasting glucose levels
of 220 mg/dL or less (≤12.2 mmol/L), left ventricular
ejection fractions of 25% or greater, and absence of
symptomatic congestive heart failure.
Perspective
The cost-effectiveness of lipid-lowering therapy using
the CARE criteria was analysed from a societal per-
spective with respect to the benefits. The perspective
of the health service was considered with regard to
costs and savings.
Costs
Local costs of treatment were used in the analysis and
were derived by combining the costs of drug treatment
and lipid measurements for a period of 5 years. All
monetary values were calculated for 1997/1999 in
Hong Kong dollars (US$1 = HK$7.78).
In the CARE study, patients randomised to the
active treatment group received pravastatin 40 mg/d.
The acquisition cost of a 20 mg tablet of pravastatin
was HK$7.67 for hospitals in the Hong Kong Hospital
Authority.7 The total drug cost was thus calculated as
the annual cost of two 20 mg tablets daily per patient,
multiplied by the number of patient years of treat-
ment (ie the total number of patients multiplied by the
number of years of treatment). The second cost con-
sidered was that of serum lipid measurements. In the
CARE study, measurements were completed at
baseline, at 6 and 12 weeks after randomisation,
thereafter at the end of each quarter during the first
year (ie six measurements in the first year), and semi-
annually for the remaining 4 years. Thus for patients
surviving 5 years, the number of measurements
equalled 14 in total (6 + 2 x 4). The authors undertook
a telephone survey of 10 local private clinics to estimate
the market price of a full lipid profile in Hong Kong.
The median cost of a single lipid profile measurement
was calculated at HK$440.
Cost-effectiveness analysis
Cost-effectiveness analysis is concerned with the
measurement of outcomes in natural units (eg cost per
event prevented).8 In this study, the primary endpoint
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was the cost per life saved. Secondary endpoints
included:
(1) cost per fatal or non-fatal coronary event (ie death
from CHD or non-fatal MI) prevented;
(2) cost per procedure prevented; and
(3) cost per fatal and non-fatal stroke prevented.
The endpoint figures—cost per prevention of event
—were also calculated based on the 95% confidence
intervals (CI) for the risk reduction of cardiovascular
events by pravastatin (in percentages) as determined
from the CARE trial.3 The upper limits of the CI for
risk reduction of events were used to determine the
corresponding upper limits of the number of events
prevented (original number of events prevented
multiplied by the upper limit of CI for risk reduction/
original risk reduction). Thus, the lower limits of cost
per event prevented were derived. Similarly, the upper
limits of cost per event prevented were derived from
the lower limits of the CI for risk reduction of events.
Cost-utility analysis
In the cost-utility analysis, the endpoints were gross
cost and net cost per QALY gained. This calculation
involved the summation of QALYs gained from two
sources: fatal and non-fatal MIs prevented, and fatal
and non-fatal strokes prevented. In the 4S, the average
quality of life (QOL) for the patients post-MI was
assumed as 0.88.4 Various other published studies have
proposed a QOL value for those surviving MI of
approximately 0.8 to 0.9.9,10 Thus, in this study the
average QOL for the hypothetical patients was taken
as approximately 0.85.
Unified approach
In the 4S, it was estimated that the individual’s re-
maining life expectancy was approximately halved by
a CHD event at around the age of 60 years.5 Accord-
ing to government statistics, the remaining average
life expectancy in Hong Kong at the age of 59 years is
21.28 years for males and 25.34 years for females.11
Thus, using the 4S approach, a prior MI at 59 years in
men in Hong Kong could be expected to reduce average
life expectancy by 10.64 years. For males meeting
the entry criteria for the CARE study (ie past MI), a
further MI (fatal or non-fatal) was assumed on average
to decrease remaining life expectancy at the age of
59 years by a further half (ie 10.64/2 years). Thus,
the QALYs gained from the prevention of MI could be
calculated as: (number of second MIs prevented) x
(average number of life years gained) x 85%. Con-
sequently, in males the average QALYs gained per MI
prevented was estimated as 10.64/2 years x 85%.
Correspondingly in females, this equated to 12.67/2 x
85%. In Hong Kong, the ratio of males to females with
MI at the age of 50 to 59 years is 6.45:1,12 giving an
average life expectancy in these combined groups of
10.91 years. Thus, assuming that the total number of
MIs (fatal and non-fatal) prevented by pravastatin
treatment would be the same as in the CARE study (ie
50), the QALYs gained in Hong Kong could be
estimated as 50 x 10.91/2 x 85%.
By analogy with ischaemic heart disease, it was
assumed that in patients meeting CARE entry criteria,
the average remaining life expectancy following a
fatal or non-fatal stroke would similarly decrease by
half (ie 10.91/2). Thus, the QALYs gained from strokes
prevented were calculated as: (number of strokes
prevented) x (number of corresponding life years
gained) x 85%. Extrapolating from the total number
of strokes prevented in the CARE study (ie 24),13 the
QALYs gained in Hong Kong could be estimated as
24 x 10.91/2 x 85%.
Alternative approach
For this approach to the calculations, the assumption
made was of a 50% average reduction in remaining
life expectancy for patients sustaining a non-fatal MI.
For patients sustaining a fatal MI at some time during
the ensuing 5 years of the trial, a 75% average reduction
in remaining life expectancy (at age of 59 years) was
assumed. The resulting gain in QALYs from the
prevention of fatal MIs (ie 14 x 10.91 x 0.75 x 0.85),
non-fatal MIs (ie 38 x 10.91 x 0.5 x 0.85), and strokes
attributed to statin therapy was recalculated on this basis.
Discounting of costs
The budget for the pravastatin tablets and the lipid level
testing was estimated as if such costs were incurred at
the beginning of a typical 5-year treatment course. In
actuality, such expenditure was incurred throughout
the course of treatment. For this reason, a further
calculation was made, discounting gross cost at the
respective rates of 6% and 4% per annum. These
discounted rates were applied to the cost-effectiveness
and cost-utility (unified and alternative approach)
analyses.
Discounting of quality-adjusted life years gained
In addition to discounting gross cost to calculate gross
cost per QALY gained, the number of QALYs gained
was also discounted at 6% per annum in the cost-utility
analysis under both unified and alternative approaches.
Sensitivity analysis
The endpoint results could be varied if different
assumptions were made in the calculations of the two
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approaches. Two types of sensitivity analyses were
performed on the gross cost per QALY gained before
discounting: (1) by changing the expected QOL after
MI; and (2) by modifying the extent to which fatal and
non-fatal MIs decreased the average remaining life
expectancy of patients. Thus, QOLs of 0.8 and 0.9
instead of 0.85 were considered. Similarly, average
remaining life expectancy after fatal or non-fatal
MI (unified approach) were considered to decrease by
40% and 60% instead of 50%. For the alternative
approach, 40% and 65% as well as 60% and 85%
reductions (instead of 50% and 75%) in life expectancy
for non-fatal and fatal MIs respectively, were taken
into account.
Further analysis of net cost: potential savings
In order to estimate net cost per QALY gained in the
cost-utility analysis, all potential savings were de-
ducted from the gross cost to obtain the net cost. In
addition to estimations without discounting, the
potential savings were discounted at 6% per annum.
The net cost per QALY gained was thus calculated
with both non-discounted and discounted net costs and
benefits. Savings that were considered arose from three
sources:
(1) prevention of non-fatal MIs;
(2) prevention of procedures; and
(3) prevention of non-fatal strokes.
Prevention of non-fatal MIs implied the saving of
an acute admission (38 x cost of admission). The
average cost of each admission for a patient with acute
MI was determined as HK$46 720, based on a cost
estimation provided by accountants in the finance
division of Queen Mary Hospital.
The rate of procedures was reduced by treatment
and a corresponding reduction in the use of stents was
expected. A survey of the prices charged for percutan-
eous transluminal coronary angioplasty (PTCA) and
the use of stents in patients with heart disease was
undertaken at Queen Mary Hospital. The most recent
patients (n=120) who underwent PTCA were
evaluated. The median cost of a PTCA procedure was
$35 000 (mean, $29 195.83; standard deviation [SD],
$11 504.92; range, $14 000-$48 000) and the median
price for stenting was $12 000 (mean, $12 767.50; SD,
$13 963.24; range, $0-$65 600). By using these median
costs, the savings resulting from the prevention of the
47 PTCA and stenting procedures were estimated.
In the CARE study, 28 non-fatal strokes were
prevented. Calculation of benefits due to stroke
prevention was based on the assumption of an equal
distribution of severe and mild disabilities prevented.
The health care for stroke patients depends on the
degree of severity of their disabilities. For the preven-
tion of 14 severe disabilities, it was assumed that
savings from attending a geriatric day hospital with
supervised daily therapy were made. According to a
local publication on hospital charges for persons not
entitled to government subsidised services,14 the
cost of geriatric day hospital care was HK$1430 per
attendance. This saving was interpreted as the daily
cost multiplied by the life span of those with severe
disabilities (10.91 x 0.5) expressed in days (HK$1430
x 14 x 10.91 x 0.5 x 365). For the prevention of 14
mild disabilities, it was assumed that community
nursing services (two visits per week per patient) might
be saved. The cost of the community nursing service
was HK$360 per patient per visit in Hong Kong.14
Thus, the savings from care of mild disabilities
prevented were calculated as the weekly cost multiplied
by the life span of patients with mild disabilities
(10.91 x 0.5) expressed in weeks ($360 x 2 x 14 x 10.91
x 0.5 x 52).
Results
Cost figures
The cost of prescribing pravastatin 40 mg/d (365
days x 5) for 2081 patients was estimated to be
HK$58 258 636. Using the median market price for a
full lipid profile of HK$440 (mean, $441; range, $350-
$650) derived from the telephone survey, the cost of
lipid measurements was estimated at HK$12 818 960.
Hence, the combined costs comprised a total of
HK$71 077 596.
Cost-effectiveness results
To evaluate the benefits of active treatment, the results
of the pravastatin and placebo groups in the trial were
compared. The number of events prevented by
pravastatin treatment, including deaths (all-cause
including CHD), non-fatal MI, procedures, and strokes
are shown in Table 1, together with the respective cost
per event prevented. The calculated endpoints of cost
per life saved or death prevented was HK$4 442 350;
the cost per fatal or non-fatal cardiac event (CHD
death or non-fatal MI) prevented was HK$1 146 413;
the cost per procedure prevented was HK$732 759; and
the cost per fatal or non-fatal stroke prevented was
HK$2 961 566. The corresponding upper and lower
estimates for cost per event prevented is also shown
in Table 1. In the case of all deaths and CHD deaths,
the upper limits for cost per event prevented were
undefined, because the lower limits of the 95% CI for
risk reduction of these events with active treatment
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were negative numbers, implying that no deaths were
prevented.
Cost-utility results
Unified approach
The total gain in QALYs under the unified method of
calculation was 231.84 years from the prevention of
fatal and non-fatal MIs, and 111.28 years from the
prevention of fatal and non-fatal strokes. Total QALYs
gained thus amounted to 343.12 years and the result-
ing gross cost per QALY gained was HK$207 151,
assuming no overlap and without discounting.
Alternative approach
When fatal MIs during the 5 years of the trial were
assumed to decrease remaining life expectancy by 75%
on average, the QALYs gained from their prevention
totalled 97.37 years. For non-fatal MIs, prevention led
to a gain in QALYs of 176.20 years. Thus, the total
QALYs gained were 384.85 years, together with 111.28
QALYs gained from the prevention of fatal and non-
fatal strokes, calculated previously. The gross cost per
QALY gained, assuming no overlap and without
discounting, was thus HK$184 689 using this second
method of calculation.
Discounting of costs
The cost of drugs prescribed and lipid level measure-
ments decreased to HK$49 081 313 and HK$11 431 563,
respectively when they were discounted at 6% per
annum. Thus, discounted total costs at 6% amounted
to HK$60 512 876. With discounting at 4% per annum,
the cost of drug and lipid measurements amounted
to HK$51 871 419 and HK$11 855 865, respectively;
hence HK$63 727 284 in total. Non-discounted and dis-
counted costs per event prevented are summarised in
Table 1. Gross costs per QALY gained with, and with-
out discounting costs, using the unified and alternative
approaches are summarised in Table 2.
Discounting of quality-adjusted life years gained
Using the unified approach to estimating QALYs
gained, the discounted QALYs at 6% per annum were
195.32 years from fatal and non-fatal MIs prevented,
and 93.75 years from fatal and non-fatal strokes
prevented. Thus, the total discounted QALYs gained
were 289.07 years using the unified approach. Using
the alternative approach, the discounted QALYs gained
were 82.03 years from fatal MIs prevented, 148.44
years from non-fatal MIs prevented; and 93.75 years
from fatal and non-fatal strokes prevented. Thus, the
total discounted QALYs gained were 324.22 years
using the alternative approach. In combination with
the discounted gross costs at 6% ($60 512 876) as
calculated previously, discounted gross costs per QALY
gained using the unified and alternative approaches
in the cost-utility analysis were HK$209 336 and
HK$186 641, respectively.
Table 1. Cost-effectiveness over 5 years without and with discounting
Event No. of event Cost per event prevented (HK$)
prevented (lower limits to upper limits)
No discounting 4% discounting 6% discounting
Deaths 16 4 442 350 3 982 955  3 782 055
(1 537 736 to undefined*) (1 378 715 to undefined*) (1 309 173 to undefined*)
Coronary heart 23 3 090 330 2 770 751 2 630 995
disease deaths (1 584 785 to undefined*) (1 420 898 to undefined*) (1 349 228 to undefined*)
Non-fatal MIs† 38 1 870 463 1 677 034 1 592 444
(1 103 094 to 10 755 162) (989 020 to 9 642 944) (939 134 to 9 156 554)
Fatal or confirmed 50 1 421 552 1 274 546 1 210 258
non-fatal MIs (911 251 to 4 442 350) (817 016 to 3 982 955) (775 806 to 3 782 055)
Coronary heart 62 1 146 413 1 027 859 976 014
disease deaths (764 275 to 3 057 101) (685 240 to 2 740 958) (650 676 to 2 602 704)
or non-fatal MIs
Procedures 97 732 759 626 982 623 844
(534 716 to 1 318 966) (479 420 to 1 182 568) (455 238 to 1 122 919)
Fatal and 24 2 961 566 2 655 304 2 521 370
non-fatal strokes (1 822 502 to 23 692 532) (1 634 033 to 21 242 428) (1 551 612 to 20 170 959)
All events (deaths + 179 397 082 356 018 338 061
non-fatal MIs +
non-fatal strokes +
procedures)
* The upper limits of costs are undefined since no events were prevented as implied by the lower limits of the 95% CI of risk reduction with
pravastatin given in the CARE study
† MI myocardial infarction
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Sensitivity analysis
Gross cost per QALY gained was tested for sensitivity to
the values for expected QOL after MI. The degree to
which non-fatal and fatal MIs reduced the average
remaining life expectancy of patients, and thus the
gain attributable to their prevention, was subject to un-
certainty. In the unified approach, gross cost per QALY
gained increased from HK$207 151 to HK$220 098 when
QOL was taken as 0.8, whereas when QOL increased to
0.9, it decreased to HK$195 643. Similar results were
obtained with respect to 40% and 60% reductions in
average life expectancy. For the alternative method, gross
cost per QALY gained rose less, from HK$184 689 to
HK$196 232, and fell to HK$174 428 when QOL was
assumed to be 0.8 and 0.9, respectively, with all other
variables unchanged. The results of the sensitivity analysis
are summarised in Table 3.
Further analysis: net cost per quality-adjusted life
year gained
Savings from avoiding acute admissions resulting
from the prevention of non-fatal MIs amounted to
HK$1 775 360. The prevention of PTCA procedures
saved HK$1 645 000 and the prevention of stent
deployment, HK$564 000. Thus, the procedures
prevented saved HK$2 209 000 in total. The savings
from avoiding geriatric day hospital care for stroke
patients with severe disabilities was HK$39 861 322.
The savings due to avoiding community nursing
services for stroke patients with mild disabilities was
estimated at HK$2 859 293. Thus, the monetary savings
resulting from the prevention of non-fatal strokes was
estimated at HK$42 720 615 and the total of all potential
savings HK$46 704 975 (Table 4).
Table 5 summarises the results of net cost per
QALY gained with and without discounting. Using
the unified approach with 343.12 QALYs gained and
no discounting, net cost per QALY gained from
pravastatin treatment for 5 years was calculated as
HK$71 032 ([$71 077 596-$46 704 975]/343.12). When
using the discounted gross cost (at 6%), discounted
total potential savings (at 6%), and discounted QALYs
gained (at 6%), the net cost per QALY gained became
HK$73 218 ([$60 512 876-$39 347 668]/289.07).
Applying the same method to the alternative model
with 384.85 QALYs gained, net cost per QALY
gained was estimated at HK$63 330 ([$71 077 596-
$46 704 975]/384.85); with no discounting and the
discounted net cost per QALY gained was calculated
as HK$65 280 ([$60 512 876-$39 347 668]/324.22).
Discussion
In recent years, the efficacy of statins in the preven-
tion of CHD has been well established. Secondary
Table 2. Cost-utility analysis: gross cost per quality-adjusted life year gained over 5 years without and with
discounting costs
Gross cost per quality-adjusted life year gained (HK$)
No discounting 4% discounting* 6% discounting*
Unified approach 207 151 185 729 176 361
Alternative approach 184 689 165 590 157 237
* Costs of drug treatments and lipid measurements were discounted at 4% and 6% per annum for 5 years. The present value of drug
cost=∑ c / (1 + r)n, for n=1 to 5; where c=cost of drug treatments for 2081 patients per year and r=discount rate. The present value of lipid
measurements = m + m / [(1 + r)1/8 -1] + ∑ m / [(1 + r) 1/4 - 1]n, for n=1 to 4 and n=6, 8, 10, 12, 14, 16, 18, 20; where m=cost of each lipid
measurement for 2081 patients and r=discount rate
Table 3. Sensitivity analysis: effect of quality of life adjustments and reduction in life expectancy due to fatal or
non-fatal myocardial infarction on costs per quality-adjusted life year gained
Cost per quality-adjusted life year gained (HK$)
Unified approach Reduction in average remaining life expectancy*
Quality of life 40% 50% 60%
0.8 254 488 220 098 193 896
0.85 239 519 207 151 182 490
0.9 226 212 195 643 172 352
Alternative approach Reduction in average remaining life expectancy*
Quality of life non-fatal MI†: 40% non-fatal MI: 50% non-fatal MI: 60%
fatal MI: 65% fatal MI: 75% fatal MI: 85%
0.8 224 342 196 232 174 382
0.85 211 146 184 689 164 124
0.9 199 415 174 428 155 006
* at age of 59 years
† MI myocardial infarction
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prevention studies have shown that patients benefit
whether they have high or normal cholesterol levels.2,3
In primary prevention, the West of Scotland Coronary
Prevention study15 revealed benefits from treating
hypercholesterolaemic men with pravastatin. More-
over, the Air Force/Texas Coronary Atherosclerosis
Prevention study16 suggested that treatment with
lovastatin conferred benefits in subjects without CHD
and with average serum cholesterol levels. The results
of the above trials suggest that, regardless of the level
of risk, recipients benefit from treatment with statins
in terms of cardiovascular event prevention.17 Hence,
economic evaluation is needed to determine whether
such benefits are affordable and whether spending
money on statins for those with normal cholesterol
levels is a good use of resources.
The definition of economic evaluation is “the
comparative analysis of alternative courses of action
in terms of both costs and consequences”.18 This study
involved both a cost-effectiveness and cost-utility
analysis. Cost-effectiveness analysis is one method of
economic evaluation which allows comparisons of
interventions by their cost per consequence in natural
units, such as cost per life saved or life year gained.19
Cost-utility analysis, a form of cost-effectiveness
analysis, is used when single-dimension outcomes are
not possible, for example, when the interventions
produce differing consequences in terms of quantity
and quality of life. The latter takes into account the
quality of the individual’s resulting health state as well
as the number of extra years of life and expresses the
combination of these in a unit of utility such as QALYs.
Interventions can then be compared by means of a cost
per unit of utility gained, for example, cost per QALY
gained.19
In the economic model of this study, estimations
derived from stroke prevention are included. Apart
from the risk reduction data for stroke obtained from
the CARE study, there is recent evidence confirming
that treatment with statins can reduce the incidence of
stroke. The Long-Term Intervention with Pravastatin
in Ischaemic Disease study,20 a secondary prevention
study in 9014 patients with a broad range of cholesterol
levels, shows that treatment with pravastatin reduces
the risk of stroke by 19%. This finding is consistent with
that of the 4S, which illustrated that a risk reduction
of 28% in stroke could be achieved with simvastatin
treatment.21 These results support the inclusion of
stroke in the current economic evaluation.
The current economic model may not contain all
potential savings in net monetary terms. The net cost
per QALY gained, however, based on available data
has been calculated. Since the estimation of costs in
these models is from a service provider’s perspective,
potential savings are similarly calculated from this
perspective. Indirect and intangible costs from the
patient’s perspective, for example, loss of earnings,
were not included.
For the calculation of cost per QALY gained, no
overlap of patients for the events was assumed. This
assumption, however, may not be correct. If there were
patients who had more than one event, then the QALYs
gained would have been overstated. This assumption
was made due to the limited information available. In
addition, the endpoint results of the current analyses
may be subject to high variability as shown by the upper
and lower estimates for cost per event prevented.
A major difficulty in determining whether an
intervention is cost-effective or not is the fact that there
is no absolute level of cost-effectiveness. No standard
is available in Hong Kong to assist in determining the
Table 4. Potential savings without discounting
Source of savings Amount (HK$)
Prevention of:
Acute admission due to non-fatal MI* 1 775 360
PTCA† procedure 1 645 000
Deployment of stent 564 000
Community nursing services for mild disabilities secondary to stroke 2 859 293
Geriatric day hospital for severe disabilities secondary to stroke 39 861 322
Total savings   46 704 975
* MI myocardial infarction
† PTCA percutaneous transluminal coronary angioplasty
Table 5. Cost-utility analysis: net cost per quality-
adjusted life year gained over 5 years without and with
discounting
Net cost per quality-adjusted
life year gained (HK$)
No discounting 6% discounting*
Unified approach 71 032 73 218
Alternative approach 63 330 65 280
* Calculated with discounted gross cost, discounted total potential
savings, and discounted quality-adjusted life years gained
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appropriate cost per outcome for an intervention. For
example, does this study’s finding of a cost of almost
HK$4 million per death prevented imply that the use
of statins is cost-effective? The purpose of this study
has been to provide a basis for future comparison. In
theory, different interventions, the same intervention
for different risk groups or interventions targeted at
preventing different outcomes can be compared. From
this study, the cost per coronary event prevented
(HK$1.03 million) and the cost per stroke prevented
(HK$2.66 million) with pravastatin treatment has been
identified. The gross cost per QALY of approximately
HK$0.16 to 0.21 million (US$20 000-27 000), and net
lost per QALY of approximately HK$0.06 to 0.07
million (US$8000-9000), might be considered an
efficient investment in other health care systems where
reasonable costs per QALY range from £10 00022 to
US$50 000.23
Results of economic evaluations vary because of
differences in methodologies and the underlying
assumptions used in different studies. The problem is
magnified when studies are performed in different
countries, as respective social, cultural, and economic
factors may influence the corresponding methodology
and results. This is why data must be derived for Hong
Kong. As well as considering local cost data, QOL data
from patients in Hong Kong should be determined. In
this study, assumptions concerning QOL were based
on patient data from overseas. By applying overseas
data, it is possible that the cost per QALY gained in
the cost-utility analysis has been underestimated if the
QOL in Hong Kong patients is lower than that reference
group. Similarly, the cost per event prevented in the
cost-effectiveness analysis may have been underesti-
mated if the number of events prevented with treatment
is lower in patients in Hong Kong than those overseas.
The cost-effectiveness of treatment with statins is
highly dependent on the baseline risk of the individual
patient. Cholesterol level in itself can be a poor
indicator of future coronary risk, since the majority of
coronary events occur in patients with average
cholesterol levels. Further data is needed from
economic evaluations comparing patients at different
levels of risk and treatment with statins, an expensive
option, with other possibly more cost-effective
interventions.
Data on the cost-effectiveness of the CARE study
has not been published. There are, however, cost-
effectiveness studies available reporting the use of
statins. Ebrahim et al 24 compared the cost-effectiveness
of statins with a range of other CHD prevention
therapies. They found that the discounted gross cost
per life year gained ranged from £3800 to £9300 at
levels of risk consistent with secondary prevention, and
was high compared to other drug therapies and lifestyle
changes. Nevertheless, with a net cost per life year
gained of approximately £8000, treatment with statins
compared favourably with several other interventions
currently provided by the National Health Service.
Coronary heart disease is an increasing problem in
Hong Kong. According to local guidelines for treatment
with lipid-lowering drugs, treatment is not currently
recommended for patients with heart disease but
normal cholesterol levels.25 There is a lack of large local
clinical trials in line with the CARE study. By using
the results of the CARE study and local cost data, this
study has attempted to assess the cost-effectiveness of
such an intervention in Hong Kong. This study has
assumed that the CARE findings would be applicable
to the population in Hong Kong and that similar
benefits and gains would be observed in local patients.
More local studies are needed investigating these
issues, in particular appropriate weightings for QOL
following CHD events. This information would allow
accurate estimations of costs, and decision-makers to
consider whether these costs can be met given the
identified benefits. The results of this study and others
like it will assist in appropriate prioritisation and
allocation of health care resources in Hong Kong.
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